Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
BIL also holds an option to increase its equity stake by an additional 15%
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Encouraging early detection and breaking the silence around men’s health
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
